Skip to content

Medical-device intelligence

bioMerieux Inc: FDA clearances and recalls

Research bioMerieux Inc in public FDA records: applicant and recalling-firm names, product codes, clearance history, and recall records.

Names and coverage

This profile groups matching applicant and recalling-firm names found in covered FDA records. It does not imply a complete corporate family, current ownership, or every product marketed under a brand.

Names observed in the source

Capitalization and punctuation variants are normalized. Customer-entered watchlist aliases remain private.

Product codes in this company’s records

Record activity in this scope

253 clearance records and 572 recall records in the covered releases, across 1 source company names and 88 product codes. Dated history runs from Feb 9, 1983 to Nov 4, 2026.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202500
November 202500
December 202500
January 202601
February 202600
March 202600
April 202610
May 202600
June 202601
July 202611
August 202600
September 202600
October 202610

Product codes represented

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

825 matching records
Device / recordCompany in FDA recordSourceSource date
VITEK 2 AST-Gram Negative Polymyxin B (<= 0.25 – >=16µg/mL);VITEK 2 AST-Gram Negative Imipenem (<= 0.25 – >=16µg/mL);VITEK 2 AST-Gram Negative Ce…K262807 · LONBIOMERIEUX, Inc.510(k)Nov 4, 2026FDA decision date
VITEK 2 AST-Streptococcus Meropenem (=0.06 - =4 µg/mL)K260283 · LONbioMerieux, Inc.510(k)Oct 1, 2026FDA decision date
VITEK 2 AST-N461 TEST KIT, GRAM NEGATIVE SUSCEPTIBILITY TESTING - AUTOMATED, Reference Number 424811Z-3231-2026 · LONBiomerieux IncRecallSep 18, 2026FDA classification date
VITEK 2 AST-N447 TEST KIT Product reference 424620Z-2715-2026 · LONBiomerieux IncRecallJul 9, 2026FDA classification date
VITEK REVEAL GN AST Assay and VITEK REVEAL AST SystemK260160 · SANbioMerieux, Inc.510(k)Jul 8, 2026FDA decision date
VITEK 2 AST-Streptococcus Inducible Clindamycin ResistanceK260282 · LONbioMerieux, Inc.510(k)Apr 15, 2026FDA decision date
VITEK 2 Gram-negative Susceptibility Cards Containing o Polymyxin B (pb02n) o Ceftazidime/avibactam (cza02n) o Meropenem/Vaborbactam (mev01n) o I…Z-1236-2026 · LTWBiomerieux IncRecallFeb 2, 2026FDA classification date
VITEK 2 Gram-negative AST Test Kits (Cards) containing Colistin formulation cs02n. VITEK 2 is an automated system consisting of instruments, sof…Z-2671-2025 · LONbioMerieux, Inc.RecallSep 29, 2025FDA classification date
VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)K251579 · LONbioMerieux, Inc.510(k)Aug 21, 2025FDA decision date
VITEK COMPACT PROK234012 · LONbioMerieux, Inc.510(k)Mar 14, 2025FDA decision date
VITEK 2 AST-Yeast Voriconazole (<= 0.03125 - >= 4 µg/mL)K232967 · NGZbioMerieux, Inc.510(k)Jun 12, 2024FDA decision date
VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL)K232963 · NGZbioMerieux, Inc.510(k)Jun 7, 2024FDA decision date
VIDAS TBI (GFAP, UCH-L1)K240279 · QATbioMerieux, Inc.510(k)May 1, 2024FDA decision date
VITEK 2 - AST Test kits (in vitro diagnostic test cards for antimicrobial susceptibility): a) AST-N334, REF 418984; b) AST-GN95, REF 421982; …Z-1464-2024 · LONBiomerieux IncRecallApr 25, 2024FDA classification date
VITEK 2 AST-Gram Positive Lefamulin (<=0.03 - >=4 µg/mL)K234000 · LONbioMerieux, Inc.510(k)Mar 11, 2024FDA decision date
VITEK 2 AST-Streptococcus Penicillin (<=0.06 - =>8 µg/mL), VITEK 2 Streptococcus Penicillin (<=0.06 - >=8 µg/mL), VITEK 2 Streptococcus Penicilli…K232201 · LONbioMerieux, Inc.510(k)Oct 23, 2023FDA decision date
VITEK 2 AST-Gram Positive Daptomycin (<=0.12 - >=8 µg/mL), VITEK 2 AST-GP Daptomycin (<=0.12 - >=8 µg/mL), VITEK 2 AST-GP DaptomycinK230864 · LONbioMerieux, Inc.510(k)Jul 5, 2023FDA decision date
VITEK 2 AST-Gram Negative Levofloxacin (</=0.125 ->/=8 ug/mL)K222378 · LONbioMerieux, Inc.510(k)Jun 26, 2023FDA decision date
MYLA comprises AST Filters in conjunction with VITEK MS; middleware which connects microbiology laboratory instruments for ID/AST and blood cult…Z-1201-2023 · OUGBiomerieux IncRecallMar 2, 2023FDA classification date
VITEK® 2 AST-Gram Negative Plazomicin (=0.5 - =16 µg/mL); VITEK® 2 AST-GN Plazomicin (=0.5 - =16 µg/mL); VITEK® 2 AST-GN PlazomicinK223478 · LONbioMerieux, Inc.510(k)Feb 16, 2023FDA decision date
VITEK 2 AST-Gram Negative Cefazolin (<=1 - >=32 ug/mL)K222073 · LONbioMerieux, Inc.510(k)Feb 9, 2023FDA decision date
VITEK® 2 Streptococcus Tetracycline (<=0.25 - >=16 µg/mL)K223481 · LONbioMerieux, Inc.510(k)Feb 3, 2023FDA decision date
VITEK 2 AST-Gram Positive Moxifloxacin (=0.25 - =8 µg/ml), VITEK 2 AST-GP Moxifloxacin (=0.25 - =8 µg/mL), VITEK 2 AST-GP MoxifloxacinK220803 · LONbioMerieux, Inc.510(k)Jan 27, 2023FDA decision date
API LISTERIA 10 STRIPS+10 MEDIA, CATALOG 10300Z-0783-2023 · JTOBiomerieux IncRecallJan 4, 2023FDA classification date
API 20 E 25 STRIPS, CATALOG 20100Z-0784-2023 · JSSBiomerieux IncRecallJan 4, 2023FDA classification date

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗